All In Biotech

Drug Trial Radar · NCT06370039

Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease

Phase 2, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study of INV-102 Ophthalmic Solution in Adult Subjects With Moderate to Severe Dry Eye Disease

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 109 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

109

Actual

Start

Mar 27, 2024

Primary completion

Jul 3, 2024

Study completion Jul 3, 2024

Sponsor

Lead sponsor
Invirsa, Inc.Industry
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority
First posted
Apr 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease.

Conditions

  • Dry Eye Disease

Interventions

  • INV-102Drug

    INV-102 Ophthalmic Solution

  • VehicleDrug

    Vehicle Ophthalmic Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in corneal fluorescein staining total score on the National Eye Institute (NEI)/Industry scaleTime frame: Baseline to Day 29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • iuvo BioScience

    Rush, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.